atorvastatin has been researched along with topiroxostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Han, X; Huang, H; Ji, Y; Liu, Y; Luo, Z; Sun, W; Wang, G; Yang, T; Yu, G | 1 |
1 review(s) available for atorvastatin and topiroxostat
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for atorvastatin and topiroxostat
| Article | Year |
|---|---|
Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.
Topics: Adult; Atorvastatin; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Evaluation Studies as Topic; Humans; Lactones; Middle Aged; Nitriles; Organic Anion Transporters; Pyridines; Rhabdomyolysis | 2020 |